A Feasibility Study of Weekly Docetaxel with Capecitabine in Ovarian Cancer: A Promising Combination of Two Active Drugs with a Potential for Synergism-Reference-Cited by-同舟云学术

A Feasibility Study of Weekly Docetaxel with Capecitabine in Ovarian Cancer: A Promising Combination of Two Active Drugs with a Potential for Synergism

Published:2009 Issue:4 Volume:55 Page:298-302
ISSN:1421-9794
Container-title:Chemotherapy
language:en
Short-container-title:Chemotherapy

Author:

Safra T.,Bernstein Molho R.,Menzcher J.,Inbar M.,Grisaru D.,Levy T.

Publisher

S. Karger AG

Subject

Infectious Diseases,Pharmacology (medical),Drug Discovery,Pharmacology,Oncology,General Medicine

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapy;Gynecologic Oncology;2013-07

2. A study of docetaxel weekly or every three weeks in combination with carboplatin as first line chemotherapy in epithelial ovarian cancer: Hematological and non-hematological toxicity profiles;Oncology Letters;2013-01-22

3. Phase II Study of Docetaxel Weekly in Combination With Carboplatin Every 3 Weeks as First-Line Chemotherapy in Stage IIB to Stage IV Epithelial Ovarian Cancer;International Journal of Gynecologic Cancer;2012-01

4. A phase II study of docetaxel weekly in combination with carboplatin every three weeks as first line chemotherapy in stage IIB-IV epithelial ovarian cancer: Neurological toxicity and quality-of-life evaluation;International Journal of Oncology;2011-12-07

5. Thymidine Phosphorylase/Platelet-Derived Endothelial Cell Growth Factor as a Target for Capecitabine: From Biology to the Bedsid;Frontiers in Anti-Cancer Drug Discovery;2011-03-26